An intact HDM2 RING-finger domain is required for nuclear exclusion of p53

被引:285
|
作者
Boyd, SD
Tsai, KY
Jacks, T
机构
[1] MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA
[2] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA
[3] Howard Hughes Med Inst, Coconut Grove, FL 33133 USA
关键词
D O I
10.1038/35023500
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The p53 tumour-suppressor protein is negatively regulated by HDM2. Recent reports indicate that the leucine-rich nuclear-export sequence (NES) of HDM2 enables it to shuttle to the cytoplasm, and that this activity is required for degradation of p53. However, it is unclear whether HDM2 is involved in nuclear export of p53, partly because p53 has itself been shown to contain a functional NES within its tetramerization domain. Here we show that co-expression of HDM2 with green fluorescent protein (GFP)-tagged p53 causes redistribution of p53 from the nucleus to the cytoplasm of the cell. This activity is dependent on binding of p53 to HDM2, and requires an intact p53 NES, but is independent of the HDM2 NES. A mutant of the HDM2 RING-finger domain that is unable to ubiquitinate p53 does not cause relocalization of p53, indicating that ubiquitin ligation or other activities of this region of HDM2 may be necessary for its regulation of p53 localization.
引用
收藏
页码:563 / 568
页数:6
相关论文
共 50 条
  • [31] Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction
    Yin, H
    Lee, GI
    Park, HS
    Payne, GA
    Rodriguez, JM
    Sebti, SM
    Hamilton, AD
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2005, 44 (18) : 2704 - 2707
  • [32] Inhibition of HDM2 and activation of p53 by ribosomal protein L23
    Jin, A
    Itahana, K
    O'Keefe, K
    Zhang, Y
    MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (17) : 7669 - 7680
  • [33] p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction
    Medina-Medina, Ixaura
    Martinez-Sanchez, Mayra
    Hernandez-Monge, Jesus
    Fahraeus, Robin
    Muller, Petr
    Olivares-Illana, Vanesa
    PROTEIN SCIENCE, 2018, 27 (05) : 976 - 986
  • [34] Targeting p53, hdm2, and CD19: vaccination and immunologic strategies
    Voss, RH
    Lotz, C
    Cellary, A
    Theobald, M
    BONE MARROW TRANSPLANTATION, 2000, 25 (Suppl 2) : S43 - S45
  • [35] Effect of linker on the binding free energy of stapled p53/HDM2 complex
    Im, Haeri
    Ham, Sihyun
    PLOS ONE, 2020, 15 (04):
  • [36] Targeting p53, hdm2, and CD19: vaccination and immunologic strategies
    R-H Voss
    C Lotz
    A Cellary
    M Theobald
    Bone Marrow Transplantation, 2000, 25 : S43 - S45
  • [37] Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells
    Grasberger, BL
    Lu, TB
    Schubert, C
    Parks, DJ
    Carver, TE
    Koblish, HK
    Cummings, MD
    LaFrance, LV
    Milkiewicz, KL
    Calvo, RR
    Maguire, D
    Lattanze, J
    Franks, CF
    Zhao, SY
    Ramachandren, K
    Bylebyl, GR
    Zhang, M
    Manthey, CL
    Petrella, EC
    Pantoliano, MW
    Deckman, IC
    Spurlino, JC
    Maroney, AC
    Tomczuk, BE
    Molloy, CJ
    Bone, RF
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) : 909 - 912
  • [38] ROS and p53 in Regulation of UVB-induced HDM2 Alternative Splicing
    Tong, Lingying
    Wu, Shiyong
    PHOTOCHEMISTRY AND PHOTOBIOLOGY, 2015, 91 (01) : 221 - 224
  • [39] RNAi knockdown of HdmX or Hdm2 leads to new insights into p53 signaling
    Berberich, Steven J.
    CELL CYCLE, 2010, 9 (18) : 3640 - 3641
  • [40] A Highly Potent and Cellularly Active β-Peptidic Inhibitor of the p53/hDM2 Interaction
    Hintersteiner, Martin
    Kimmerlin, Thierry
    Garavel, Geraldine
    Schindler, Thorsten
    Bauer, Roman
    Meisner, Nicole-Claudia
    Seifert, Jan-Marcus
    Uhl, Volker
    Auer, Manfred
    CHEMBIOCHEM, 2009, 10 (06) : 994 - 998